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Abstract
Background: Recent trials have shown that the addition of external beam radiotherapy
(EBRT) to androgen deprivation therapy (ADT) improves survival among men with
locally advanced prostate cancer.
Objective: To examine the potential impact of these trials on changes in clinical practice
and life-years saved.
Design, setting, and participants: A model was developed to examine the impact of
changes in clinical practice in the UK. A survey of clinicians who treat men with prostate
cancer in the UK and Canada was performed.
Measurements: Outcomes of interest were the proportion of patients treated with
different approaches and the predicted number of life-years saved due to changes in
clinical practice. Survey data were cross-tabulated and Pearson’s x2 tests were applied.
Results and limitations: The survey was completed by 193 clinicians (105 from the UK,
80 from Canada), of whom 70% were clinical/radiation oncologists, 8% were medical
oncologists, and 15% were urologists. UK respondents were more likely to report a
change in practice in response to the results (44% UK vs 21% Canada). Canadians were
more likely to have already been using ADT plus radiotherapy (77% Canada vs 56% UK).
The increase in the proportion of patients in the UK treated with ADT + EBRT could result
in around 3730–5177 extra life-years at 15 yr from a cohort of 7930 men diagnosed in a
single calendar year, compared to if all had been treated with ADT alone.
Conclusions: Trial ﬁndings have changed clinical practice, meaning that men with
locally advanced prostate cancer are likely to survive longer.
Patient summary: Doctors in the UK have changed practice in response to evidence on
the superiority of hormone therapy plus radiotherapy to hormone therapy alone. These
changes will improve the survival of men with locally advanced prostate cancer. Further
reductions in the use of hormone therapy alone could further improve survival.
# 2015 European Association of Urology. Published by Elsevier B.V. This is an open
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A number of different approaches are used as primary
therapy for men with locally advanced prostate cancer,
including external beam radiotherapy (EBRT) alone, andro-
gen deprivation therapy (ADT) alone, ADT + EBRT, radical
prostatectomy (RP), high–dose-rate (HDR) brachytherapy,
and observation with symptomatic interventions when
required. There are varying levels of evidence for these
approaches.
During the 1980s, Radiation Therapy Oncology Group
(RTOG) and European Organisation for Research and
Treatment of Cancer (EORTC) trials were carried out
comparing EBRT alone to EBRT plus ADT. The results of
these trials showed that the EBRT + ADT combination had
better outcomes than EBRT alone [1–3]. However, these
studies lacked an ADT-alone arm, and it was therefore not
possible to distinguish between benefits arising from ADT or
EBRT. Three randomised controlled trials (RCTs) addressing
this question have now been carried out and have shown that
addition of EBRT to ADT improves overall survival for men
with locally advanced prostate cancer [4–7]. ADT + EBRT is
the only therapeutic approach backed by published level 1
evidence for this group of patients. There is evidence from
case series and cohort studies to suggest that outcomes after
surgery for locally advanced disease can be excellent [8], but
there are no randomised trials in this setting.
We examine how evidence showing the benefit of ADT +
EBRT has influenced treatment for men with locally
advanced prostate cancer in the UK and Canada. We report
the results of a model developed to estimate the potential
number of life years saved due to changes in practice in the
UK. Model inputs were derived from a survey of clinicians.
This model may help to quantify potential survival gains at a
population level on implementation of clinical trial results.
2. Materials and methods
2.1. Impact modelling
Overall survival for patients treated with either ADT alone or ADT + EBRT
was estimated at yearly time points after randomisation from trial data
(PR.3/PR07 [7], trial registration numbers ISRCTN24991896 and
NCT00002633) to a maximum of 11 yr, after which fewer than
100 patients were still at risk. These estimates were smoothed and
extrapolated for up to 15 yr from randomisation using fractional
polynomial models with either two or four degrees of freedom
[9]. Models with four degrees of freedom are reported because of their
superior ﬁt (p < 0.0001). The ﬁtted survival functions are given by
ADT alone at time t ¼ exp exp 0:4825:288 timeð Þ
0:5
þ0:0918 timeð Þ
  !  !
and
ADT þ EBRT at time t ¼ exp exp 3:8791:350 timeð Þ
1
þ1:087 timeð Þ0:5
  !  !
:
We estimated the number of extra life years saved due to the shift
from ADT alone to ADT + EBRT for various treatment pattern scenarios,
each consistent with the survey results, for a cohort of men newly
diagnosed with locally advanced disease in the UK in a single year. Thesewere compared to the baseline scenario (73% of men treated using a
nonradical approach in 2006–2008, which we assumed to be ADT alone
for the model [10]) by calculating the area between the estimated
survival curves over 10 and 15 yr. The model was constructed in
Microsoft Excel 2010.
2.2. Data collection
2.2.1. Survey
To deﬁne the input parameters for the model described in Section 2.1, a
short online questionnaire was implemented using the Bristol Online
Surveys system (www.survey.bris.ac.uk). This collected information on
which treatment approaches respondents used for men with locally
advanced prostate cancer; awareness of the results of the PR.3/PR07
(NCT00002633) and SPCG-7/SFUO-3 trials (ISRCTN01534787); whether
these results had changed their clinical practice; views on the strength of
evidence for ADT + EBRT; further evidence needed; barriers to imple-
mentation; and priority research questions (Appendix A). Most
questions were multiple-choice.
Between November 2012 and June 2013 (more than 1 yr after the
PR.3/PR07 results were published) a link to the questionnaire was
distributed by e-mail to urologists and oncologists involved in current
prostate cancer trials run by the MRC Clinical Trials Unit or the NCIC
Clinical Trials Group (primarily UK and Canadian clinicians). Recipients
were asked to forward the e-mail to colleagues. It was also distributed to
the chairs of the Cancer Network prostate cancer site-speciﬁc groups,
who were asked to distribute it to the members of their groups. A link to
the survey was also tweeted by @MRCCTU and the European Association
of Urologists (@uroweb).
Data from the survey were analysed using Stata v.12 (www.stata.
com). Responses were cross-tabulated by country and speciality.
Pearson’s x2 tests were performed to investigate any differences. There
was no target sample size.
2.2.2. Other sources
Data for the proportion of locally advanced disease among UK men
diagnosed with prostate cancer were taken from the Cancer Research UK
website (based on National Cancer Intelligence Network data) [11]. In
2011, 41 736 new cases of prostate cancer were diagnosed in the UK
[12]. We estimate that 7930 (19%) involved locally advanced disease, The
reference scenario for the proportion of men treated with ADT alone
before results for PR.3/PR07 were published was based on data from the
National Prostate Cancer Audit of England and Wales [10].
3. Results
Table 1 shows the speciality of survey respondents by
country. Using data from Table 2 (discussed further below),
we generated five plausible scenarios to represent treat-
ment patterns in the UK in 2012–2013 (Table 3).
3.1. Modelling results
Table 3 shows an estimate of the number of life years saved
by 10 and 15 yr after diagnosis given the new treatment
patterns (scenarios 1–5) in comparison to the 2006–2008
treatment pattern had this continued (73% ADT alone) due
to the shift from ADT alone to ADT + EBRT; this necessarily
ignores other treatment approaches. The estimated cohort
comprises 7930 men diagnosed with locally advanced
disease per year. If ADT + EBRT use were to increase
from 17% to 52% and ADT alone to decrease accordingly
Table 1 – Speciality of survey respondents by country
Survey respondents, n (%)
Canada UK Other Total
Clinical/radiation oncologist 58 (73) 71 (68) 6 (75) 135 (70)
Medical oncologist 10 (13) 6 (6) 0 (0) 16 (8)
Urologist 8 (10) 19 (18) 2 (25) 29 (15)
Other 4 (5) 9 (9) 0 (0) 13 (7)
Total 80 (100) 105 (100) 8 (100) 193 (100)
Table 2 – Current approaches for treatment of locally advanced prostate cancer by country
Therapeutic approach Canada,
n (%)
UK,
n (%)
p value
(Canada vs UK)
Other,
n (%)
Total,
n (%)
ADT alone 0.002
None 9 (13) 1 (1) 3 (38) 13 (8)
<10% 51 (71) 53 (60) 3 (38) 107 (64)
10–50% 10 (14) 31 (36) 0 41 (25)
51–90% 2 (3) 2 (2) 2 (25) 6 (4)
>90% 0 1 (1) 0 1 (1)
EBRT alone 0.001
None 18 (31) 47 (65) 4 (50) 69 (50)
<10% 25 (43) 17 (24) 1 (13) 43 (31)
10–50% 12 (21) 7 (10) 2 (25) 21 (15)
51–90% 3 (5) 1 (1) 1 (13) 5 (4)
>90% 0 0 0 0
ADT + EBRT 0.041
None 2 (3) 0 0 2 (1)
<10% 0 0 1 (13) 1 (1)
10–50% 15 (20) 18 (18) 3 (38) 36 (20)
51–90% 30 (39) 57 (58) 2 (25) 89 (49)
>90% 29 (38) 24 (24) 2 (25) 55 (30)
Radical prostatectomy 0.012
None 27 (44) 19 (23) 2 (25) 48 (32)
<10% 21 (34) 44 (53) 4 (50) 69 (45)
10–50% 11 (18) 20 (24) 2 (25) 33 (22)
51–90% 2 (3) 0 0 2 (1)
>90% 0 0 0 0
Other treatment 0.319
None 24 (67) 19 (46) 3 (60) 46 (56)
<10% 9 (25) 16 (38) 2 (40) 27 (33)
10–50% 2 (6) 5 (12) 0 7 (9)
51–90% 1 (3) 1 (2) 0 2 (2)
>90% 0 0 0 0
ADT = androgen deprivation therapy; EBRT = external beam radiation.
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years by 10 yr after diagnosis, and 3730 by 15 yr. If
ADT + EBRT use were to increase from 17% to 62% (scenario
2), 2227 and 4111 life years would be saved by 10 and 15 yr,
respectively. If ADT + EBRT use were to increase from 17% to
92% (scenario 5), 2804 and 5177 life years would be saved
by 10 and 15 yr, respectively.
3.2. Survey results
As Table 1 shows, 185 clinicians responded from the
countries that recruited to the PR.3/PR07 trial and that were
targeted for the survey. Of UK respondents, 89 were from
England, 10 from Scotland, five from Wales, and one from
Northern Ireland. A further eight responses were from
Australia, Germany, Kuwait, the Netherlands, and the USA,
presumably reflecting forwarding of the invitation. Their
responses are included in the tables, but excluded from thecomparative analyses by country. Respondents who
reported ‘‘other’’ as their discipline included eight nurses
(research nurse, clinical nurse specialist, nurse consultant,
or nurse), two research radiographers, one pathologist, one
radiation therapist, and one study coordinator. As we do not
know how many people received the survey invitation via
the different distribution channels (including forwards and
tweets), we are unable to assess the response rate.
Table 2 shows the prevalence of treatment approaches
by country. The most commonly reported approach for
treatment of locally advanced prostate cancer was
ADT + EBRT. The next most common approach was ADT
alone. UK respondents were more likely to report treating a
higher proportion of their patients with ADT alone
(p = 0.002), and a lower proportion of patients with EBRT
alone (p = 0.001) than Canadian respondents. Canadian
respondents were more likely to report using ADT + EBRT
for >90% of patients than respondents from the UK
Table 3 – Life years saved in a cohort of 7930 men diagnosed in 1 yr by moving from androgen deprivation therapy (ADT) alone to ADT with
external beam radiation (EBRT)
Scenario Treatment (%) Men treated with
ADT alone per year (n)
Change in men treated with
ADT alone vs reference (n)
Life-years in
cohort saved
ADT + EBRT ADT alone
10 yr 15 yr
Reference 17 73 5789 0 0 0
1 52 24 1903 –3886 2021 3730
2 62 19 1507 –4282 2227 4111
3 72 16 1269 –4520 2350 4339
4 82 10 793 –4996 2598 4796
5 92 5 396 –5392 2804 5177
Table 4 – Awareness of and views on evidence about androgen deprivation therapy (ADT) with external beam radiotherapy (EBRT) by
country
Survey respondents, n (%)
Canada UK Other Total
Awareness of trial results
Aware of PR.3/PR07 results?
Yes, read Lancet paper 60 (81) 82 (80) 8 (100) 150 (81)
Yes, other source 12 (16) 19 (18) 0 31 (17)
No 2 (3) 2 (2) 0 4 (2)
Aware of SPCG7/SFUO3 results
Yes, read Lancet paper 42 (58) 59 (58) 6 (86) 107 (59)
Yes, other source 13 (18) 21 (21) 1 (14) 35 (19)
No 18 (25) 22 (22) 0 40 (22)
Have the results of these trials inﬂuenced your clinical practice?
Already generally using ADT + EBRT 58 (77) 56 (56) 6 (75) 120 (66)
Now generally use ADT + EBRT 16 (21) 44 (44) 2 (25) 62 (34)
Not generally using ADT + EBRT 1 (1) 0 0 1 (1)
Is the evidence strong enough for ADT + EBRT to be the standard of care for men with locally advanced prostate cancer?
Yes 68 (91) 89 (88) 6 (75) 163 (89)
No 4 (5) 4 (4) 1 (13) 9 (5)
Not sure 3 (4) 8 (8) 1 (13) 12 (7)
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approaches by discipline. Urologists were more likely to
report that a higher proportion of patients in their care were
treated with RP than other disciplines (p < 0.001), while
clinical/radiation and medical oncologists were more likely
to report that a higher proportion of patients in their care
were treated with ADT + EBRT (p < 0.001).
Table 4 shows the survey responses for awareness of the
trial evidence, impact on practice, and views on the strength
of the evidence. Nearly all respondents were aware of the
results of PR.3/PR07. The majority were also aware of the
SPCG-7/SFUO-3 results. Clinical/radiation oncologists were
more likely to report having read these papers than
urologists.
One third of respondents reported that the results had
changed their practice, and they now generally use
ADT + EBRT, while two thirds reported that it had not
changed their practice as they were already generally using
ADT + EBRT before the results were known. UK respondents
were more likely to report having changed practice in
response to the trial results than respondents from Canada,
while Canadians were more likely to have already been
using this approach (p = 0.005).Most respondents thought that the evidence is suffi-
ciently strong for ADT + EBRT to be the standard of care for
men with locally advanced prostate cancer. This varied by
speciality: 128/133 (96%) clinical/radiation oncologists,
9/14 (64%) medical oncologists and 20/29 (69%) urologists
(p < 0.001).
Table 5 presents barriers to implementation of
ADT + EBRT. The potential barriers reported as moderate
or major by >10% of respondents were toxicity concerns
and the attitudes of urology colleagues. UK respondents
were less likely than Canadian respondents to report that
the attitudes of urology colleagues (p = 0.016) or toxicity
concerns (p < 0.031) were a moderate or major barrier.
Respondents reported that pressing questions for future
research are the optimal field for EBRT, the role of RP, the
optimal ADT duration, addition of agents to ADT, the use of
HDR brachytherapy, and the optimal EBRT dose.
4. Discussion
The results of trials comparing ADT alone to ADT + EBRT are
well known to clinicians involved in treating men with
prostate cancer in Canada and the UK. This is further
Table 5 – Barriers to the use of androgen deprivation therapy with external beam radiotherapy as the routine standard of care for men with
locally advanced prostate cancer by country
Survey respondents, n (%)
Canada UK Other Total
Availability/waiting times locally
Not a barrier 66 (86) 84 (82) 8 (100) 158 (84)
Slight barrier 8 (10) 14 (14) 0 22 (12)
Moderate barrier 3 (4) 2 (2) 0 5 (3)
Major barrier 0 3 (3) 0 3 (2)
Attitudes of patients
Not a barrier 32 (42) 63 (62) 3 (38) 98 (52)
Slight barrier 36 (47) 32 (31) 4 (50) 72 (39)
Moderate barrier 9 (12) 7 (7) 1 (13) 17 (9)
Major barrier 0 0 0 0
Attitudes of urology colleagues
Not a barrier 31 (41) 64 (63) 1 (13) 96 (52)
Slight barrier 28 (37) 27 (27) 2 (25) 57 (31)
Moderate barrier 15 (20) 8 (8) 4 (50) 27 (15)
Major barrier 1 (1) 2 (2) 1 (13) 4 (2)
Attitude of oncology colleagues
Not a barrier 62 (82) 87 (86) 7 (88) 156 (84)
Slight barrier 12 (16) 12 (12) 1 (13) 25 (14)
Moderate barrier 2 (3) 2 (2) 0 4 (2)
Major barrier 0 0 0 0
Attitude of nursing colleagues
Not a barrier 74 (97) 90 (89) 7 (88) 171 (92)
Slight barrier 2 (3) 11 (11) 1 (13) 14 (8)
Moderate barrier 0 0 0 0
Major barrier 0 0 0 0
Toxicity concerns
Not a barrier 13 (18) 34 (34) 0 47 (26)
Slight barrier 43 (58) 54 (53) 3 (38) 100 (55)
Moderate barrier 18 (24) 12 (12) 4 (50) 34 (19)
Major barrier 0 1 (1) 1 (13) 2 (1)
Evidence base
Not a barrier 62 (82) 76 (75) 6 (75) 144 (78)
Slight barrier 9 (12) 22 (22) 1 (13) 32 (17)
Moderate barrier 3 (4) 3 (3) 0 6 (3)
Major barrier 2 (3) 0 1 (13) 3 (2)
Other approaches are better
Not a barrier 62 (91) 73 (85) 6 (75) 141 (87)
Slight barrier 4 (6) 13 (15) 2 (25) 19 (12)
Moderate barrier 2 (3) 0 0 2 (1)
Major barrier 0 0 0 0
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European, and North American guidelines [13–15]. Previous
surveys have shown that prostate cancer guideline recom-
mendations can lead to changes in clinical practice, such as
with the National Institute for Health and Clinical Excel-
lence in the UK [16].
In the UK there has been a shift in treatment patterns
away from ADT alone towards ADT + EBRT. The evidence
suggests that this change in practice will substantially
prolong survival (as was observed in British Columbia due
to the move away from EBRT with short-term ADT to
EBRT with long-term ADT from the late 1990s [17]).
However, between 7% and 26% of men with locally
advanced prostate cancer were still being treated with
ADT alone, which has been shown to be inferior to
ADT + EBRT. Some of these men will be unsuitable for
EBRT, but there are likely to be others who could benefit
yet are not receiving EBRT.
In Canada there has been less of a shift in treatment
patterns following the recent results. This is because use ofADT + EBRT was already much higher than in the UK.
Canadian practice changed in response to the earlier studies
showing the benefit of adding ADT to EBRT, and urologists
may have been more willing to refer their patients for
radiotherapy than was the case in the UK. At the time when
the studies of ADT + EBRT were published, many clinicians
in the UK were participating in the ongoing STAMPEDE trial,
which subsequently mandated the use of EBRT for locally
advanced disease [18] once the results of PR.3/PR07 were
published. This, too, may have influenced the change in
practice.
Our model illustrates the number of extra life years
potentially gained if ADT monotherapy decreases. We hope
our findings will encourage teams who routinely use ADT
alone for their patients with locally advanced prostate
cancer to reflect on their current practice patterns. We also
hope that patient groups will find the model results useful
in understanding the impact that clinical trials can have on
outcomes for the wider patient community, beyond trial
participants.
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using survey data with a baseline of 73% of patients in
2006–2008 receiving nonradical treatment (assumed to be
ADT alone) according to a national audit of data from
England and Wales. In settings where even more men are
treated with ADT alone, the gains from a shift to EBRT plus
ADT would be greater.
The main barriers reported in our survey to further
adoption of ADT + EBRT were concerns about toxicity and
the attitude of urology colleagues. In-depth qualitative
research may help in understanding how to address these
issues.
There are several important limitations to our study.
First, the survey was of modest size, with 193 respondents.
As clinicians were asked to forward the survey to
colleagues, we are unable to assess the response rate and
do not know how representative respondents are of the
broader clinical community treating men with prostate
cancer in the UK and Canada. In particular, we had
disappointingly few responses from urologists, despite
distribution to the network of investigators involved in
the PATCH, PR07, PROMIS, RADICALS, and STAMPEDE trials,
and those involved in studies with the NCIC Clinical Trials
Group in Canada. Details of the study were also distributed
to the chairs of the Cancer Network prostate cancer site-
specific groups, who were asked to distribute it to the
members of their groups. It is recognised that there has
been an increasing trend among urologic surgeons interna-
tionally to consider RP as a primary treatment for high-risk
locally advanced disease and we are unable to comment
accurately about the effect this might have on the results
presented here. These deficiencies in our study may impact
the generalisability of our findings, and could be an
important source of bias if urologists as a group continue
to favour surgery or ADT alone with or without supplemen-
tary therapies. Our range of scenarios presented reflects the
degree of uncertainty.
There is some evidence to suggest that outcomes after RP
for locally advanced disease may also be excellent,
particularly for younger, fitter men [8], but no RCTs
comparing outcomes for RP and ADT + EBRT for locally
advanced disease have been reported. There is a lack of
directly comparable overall survival estimates from RP,
matched for stage and age, in men with locally advanced
prostate cancer. Participants in the survey identified the
role of RP as a high-priority research question for men with
locally advanced prostate cancer. In the absence of RCT data
comparing RP versus ADT + EBRT, our model was restricted
to looking at the change from ADT alone to ADT + EBRT,
ignoring other shifts in treatment approach. We have also
extrapolated survival beyond the time periods reported by
trials, which may introduce errors into the model.
One further limitation is that the model looks only at
survival and does not consider other outcomes that may be
important to patients, such as quality of life. While the
factors addressed in patient-reported outcomes are impor-
tant, the lack of comparability between trials in how these
are measured makes it particularly difficult to blend such
information into the model.Finally, our model assumes that survival from the
treatment approaches will not improve further over the
next 10 yr. This is unrealistic; improvements from ongoing
research, notably in the castrate-refractory setting, may yet
lead to better survival than that predicted by the model.
The best way to measure changes in clinical practice
would be through the collection of high-quality routine data
from national registries. These should include information
on staging and treatments. However, at the time of the
baseline estimate for the model, such high-quality, detailed
data were not being collected nationally in the UK [19],
where the survey results indicated the most potential for
impact. For example, there is considerable variation in
estimates of what proportion of new prostate cancer
diagnoses in the UK involved locally advanced disease.
Data reported in the National Prostate Cancer Audit in
England and Wales first report indicates that for 2006–
2008, 61% of new diagnoses involved locally advanced
disease (varying from 42% to 86%, and with completeness of
staging information varying from 20% to 78% between
cancer networks) [10]. This contrasts markedly with the
data from the Eastern Office of the National Cancer
Registration Service for 2008–2010 (acknowledged as
having the best prostate cancer staging data of the English
cancer registries), where 14.8% of new diagnoses were
locally advanced disease (personal communication, D.
Greenberg, Cambridge, UK). For our model we chose to
estimate the cohort size from the value published on the
Cancer Research UK website, which is based on National
Cancer Intelligence Network data for 2012 [9], as it was both
recent and nationally representative.
Collection of data of this type is improving in the UK,
facilitated by initiatives such as the National Cancer
Intelligence Network [20] and the England and Wales
National Prostate Cancer Audit [21]. These data sets could
be invaluable in refining our model in future years, and
could yield extra information about the treatment choices
made by urologists and others. Data such as these are
important for assessing the extent to which men are
receiving the best available treatments, and identifying
areas where improvements could be made. In the absence of
registry data for the time period of interest, we had to rely
on data reported in the survey, recognising its limitations, to
allow us to estimate the impact of the PR.3/PR07 and SPCG-
7/SFUO-3 trials.
The results of trials are not the only factor that influences
clinical decisions, so we cannot assume that a trial
demonstrating a significant survival advantage from a
treatment approach will automatically change practice.
Research of this type is important to assess the extent to
which knowledge is translated into changes in practice and,
ultimately, patient benefits. This can help to demonstrate
the value of clinical trials and identify where there is
potential for further improvement in patient outcomes.
Further research should be conducted to explore the impact
of other practice-changing trials. This type of research is
essential in demonstrating the value of clinical trials in
advancing the outcomes of patients, regardless of the
disease or intervention tested.
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Clinicians in the UK and Canada have already responded to
emerging evidence on the superiority of ADT + EBRT to ADT
alone for treating locally advanced prostate cancer. The
resulting changes in practice mean that collectively, men
with this condition will survive longer. Further reductions
in the numbers of men treated with ADT alone could lead to
even better survival. ADT + EBRT is the only gold-standard
therapeutic approach backed by level 1 evidence for the
radical treatment of locally advanced prostate cancer. Until
this changes, ADT + EBRT should be regarded as a standard
of care for all men with locally advanced prostate cancer fit
enough to receive radical local treatment.
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Appendix A
Survey questions
1. Which nation do you work in?
2. What is your discipline?
Clinical oncologist
Medical oncologistUrologist
Other
3. What proportion of your patients with newly diagnosed
locally advanced prostate cancer do you treat with the
following approaches?
Hormone therapy alone
Radical prostatectomy
External beam radiotherapy alone
Hormone therapy and radiotherapy
Other
4. If you treat men with locally-advanced prostate cancer
with an approach not listed in question 3, please specify what
that approach is here
5. Were you aware of the results of the MRC PR07 / NCIC PR.3
trial?
6. Were you aware of the results of the SPCG-7/SFUO-3 trial?
7. Have the results of the PR07/PR.3 and SPCG-7/SFUO-3 trials
inﬂuenced how you treat patients with locally advanced
prostate cancer?
8. Do you think the evidence on adding radiotherapy to hormone
therapy is strong enough for this to be the routine standard
of care for men with locally advanced prostate cancer?
9. How important are the following factors as barriers to
hormone therapy + radiotherapy being the routine standard
of care for men with locally advanced prostate cancer?
Availability / waiting times locally
Attitudes of patients
Attitudes of urology colleagues
Attitude of oncology colleagues
Attitude of nursing colleagues
Toxicity concerns
Evidence base
Other approaches are better
10. Are you currently supporting any trials that recruit patients
with locally advanced prostate cancer?
11. What is the most pressing research question for men with
locally advanced prostate cancer currently?
12. Any other comments?
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